2. Academic Validation
  3. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists

Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists

  • J Med Chem. 2006 Jun 1;49(11):3402-11. doi: 10.1021/jm060031q.
Yong Gong 1,  J Kent Barbay,  Alexey B Dyatkin,  Tamara A Miskowski,  Edward S Kimball,  Stephen M Prouty,  M Carolyn Fisher,  Rosemary J Santulli,  Craig R Schneider,  Nathaniel H Wallace,  Scott A Ballentine,  William E Hageman,  John A Masucci,  Bruce E Maryanoff,  Bruce P Damiano,  Patricia Andrade-Gordon,  Dennis J Hlasta,  Pamela J Hornby,  Wei He
Affiliations

Affiliation

  • 1 Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh & McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477, USA. ygong@prdus.jnj.com
PMID: 16722660 DOI: 10.1021/jm060031q
Abstract

A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha4beta1/VCAM-1 and alpha4beta7/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha4beta1 and alpha4beta7 were generated from an amide subseries; antagonists selective for alpha4beta7 were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha4beta7-selective member of the carbamate subseries (36c), upon oral administration, demonstrated in vivo efficacy in the mouse DSS colitis model.

Figures
Products